DENTSPLY SIRONA Inc. research snapshot
XRAY AI stock analysis reads DENTSPLY SIRONA as a global dental equipment, consumables, orthodontics, and urology company that is still restructuring after years of GAAP losses and heavy debt. At the August 4, 2026 data cutoff, XRAY closed at $14.13 on August 3, 2026, with a verified market capitalization of about $2.83 billion. The stock trades near 9.6x forward adjusted EPS, carries a dividend yield near 4.5%, and has a consensus Hold rating with a $13.38 average target that sits below the current price. Q2 2026 earnings are scheduled for August 6, 2026. This page uses scenarios, technical levels, and source-backed facts. It is informational research, not investment advice.
Current price
$14.13
Market cap
$2.83 billion
AI score
58 / 100
Rating
Dental leader in restructuring, trading near 52-week high with balance-sheet risk
Trend status
Bullish recovery above both moving averages, near 52-week high
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | DENTSPLY SIRONA is one of the largest global dental equipment and consumables makers with leading positions in imaging and CAD/CAM (CEREC), endodontics, restorative, orthodontics (SureSmile), implants, and Wellspect urology catheters. The business has recurring consumable and service revenue, but revenue has declined for four straight years and GAAP losses continue. | Medium |
| Moat | The moat comes from installed equipment base, 140+ year brand heritage, regulatory approvals, global distribution, and R&D. It has narrowed as Align Technology dominates clear aligners and digital dentistry workflows face faster competitors in intraoral scanning and 3D printing. | Medium |
| Management | New CEO Daniel Scavilla took over on August 1, 2025, after leading Globus Medical through the NuVasive integration. New CFO John Fortson joined effective July 20, 2026, from Kymera International. The team is credible but unproven, and the balance sheet limits strategic flexibility. | Medium |
| Financial trend | TTM revenue is about $3.68 billion with a TTM GAAP net loss of -$628 million, or -$3.15 diluted EPS, driven by impairment and restructuring charges. FY2025 revenue fell 2.98% and free cash flow dropped to about $104 million. Q1 2026 revenue was $880 million with adjusted EPS of $0.27 and a 14.7% adjusted EBITDA margin. | High |
| Valuation | At $14.13, XRAY trades near 9.6x forward adjusted EPS, 0.77x price/sales, 2.15x book value, and about 27x price to levered free cash flow, with a dividend yield near 4.5%. The three-year scenario framework points to a bearish area near $6 to $9, a base area near $12 to $17, and a bullish area near $22 to $26. | Medium |
| Technical trend | XRAY has rallied roughly 50% from the $9.41 52-week low and now trades above both the 50-day moving average near $11.49 and the 200-day moving average near $11.81, close to the 52-week high of $14.86. RSI is near 64, approaching overbought. Short interest is high at about 15% of float, which can amplify moves. | Medium |
| Risk level | Key risks are about $2.35 billion of debt with a debt-to-equity ratio near 178%, still-negative GAAP earnings, competitive pressure in clear aligners and digital dentistry, dental procedure volume sensitivity to consumer spending, covenant and refinancing risk, and potential equity dilution. | Medium-high |
| AI confidence | High for descriptive research, market data, moving averages, and ratio math. Lower for turnaround probability because Q2 2026 results and restructuring execution are not yet public. | Medium |
| Investment certainty | Low to medium. Real assets and global reach support the base case, but the debt load and still-negative GAAP earnings create a wide range of outcomes, and the stock now sits above the consensus price target. | Low |
XRAY AI stock forecast
The XRAY AI stock forecast uses scenario math around the $14.13 close and forward adjusted EPS estimates near $1.42 to $1.47. The three-year framework produced a bearish area near $6 to $9, a base area near $12 to $17, and a bullish area near $22 to $26. The base range includes the $13.38 analyst average target, which is below the current price and reflects a market that already prices in substantial restructuring success.
$22 to $26
More likely if Q2 2026 and full-year results beat, adjusted margins expand toward pre-restructuring levels, debt is reduced, GAAP profitability returns by 2027, and the market rewards normalized earnings with a double-digit multiple.
$12 to $17
More likely if adjusted EPS recovers modestly toward $1.60 to $1.70 over three years, restructuring stabilizes margins, debt stays manageable, and investors hold the multiple near 9x. The $13.38 analyst average target sits inside this range.
$6 to $9
More likely if dental demand weakens, competitive losses in clear aligners and digital dentistry accelerate, debt covenants tighten or refinancing becomes costly, and the market values adjusted earnings near 5x or lower.
XRAY AI technical analysis
XRAY AI technical analysis turns constructive. The stock is up about 50% from the $9.41 52-week low and closed at $14.13 on August 3, 2026, above both the 50-day moving average near $11.49 and the 200-day moving average near $11.81. This is a meaningful change from earlier in 2026, when price sat below the long-term average. Levels should be refreshed with live chart data before trading.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $14.13 | August 3, 2026 closing quote used for market cap and valuation math at the data cutoff. |
| Near support | $13.40 to $13.50 | Recent July pullback lows near $13.37 to $13.49. A hold above this band keeps the short-term uptrend intact. |
| Moving-average support | $11.80 to $12.00 | The 200-day moving average near $11.81 and the 50-day average near $11.49 sit in this zone. The rally stays valid while price holds above them. |
| Deeper support | $9.40 to $10.20 | The $9.41 52-week low and the early June base area are the ultimate support reference. A break below would signal that the recovery has failed. |
| Near resistance | $14.40 to $14.90 | The July 29 high of $14.44 and the 52-week high of $14.86 form the first resistance zone. A breakout would open the way to higher levels. |
| Upper resistance | $16.00 to $17.00 | Analyst high targets of $17.00 and the mid-2025 supply area are the next resistance if the recovery extends. |
| 50-day moving average | Approximately $11.49 | Price trades well above this short-term trend gauge, supporting the recovery. |
| 200-day moving average | Approximately $11.81 | Price is now above this long-term trend gauge for a sustained stretch, a positive structural signal. |
| Momentum | Bullish but extended | RSI near 64 after a two-month rally of roughly 50%. Momentum supports the trend but leaves the stock closer to overbought territory. |
| Volume | About 5.1 to 5.9 million average daily shares | Rally days have printed above-average volume, such as 7.1 million shares on August 3, suggesting genuine buying interest. |
| Volatility | Elevated around events | Beta is 0.89, but the stock swung from about $9.40 to $14.86 within two months. Q2 2026 earnings on August 6, 2026 are the near-term volatility trigger. |
| Invalidation | Close below $12.00, then $11.00 | A close below the $11.80 to $12.00 moving-average zone would weaken the trend setup. A move back below $11.00 would suggest the recovery is not holding. |
XRAY AI trading strategy
The XRAY AI trading strategy is a rules-based research framework for a dental equipment company in restructuring with high debt leverage and a stock that has rallied sharply off its lows. It is not personal advice and should be paired with live quotes, the August 6, 2026 earnings report, position sizing, and risk controls.
Watch for a sustained close above the $14.44 July high and the $14.86 52-week high on rising volume, ideally confirmed by a strong Q2 2026 report, debt-reduction progress, and higher analyst estimates.
A close back below the 200-day moving average near $11.81, or a sharp post-earnings reversal below $12.00, should invalidate the long setup.
If XRAY pulls back toward the $12.70 to $13.50 support band without a fundamental surprise, compare the price with Q2 results, free cash flow, debt levels, and restructuring milestones before acting.
Do not add below $12.00 without a defined loss limit, because the debt load and still-negative GAAP earnings raise the downside if dental demand stalls.
Track Q2 2026 revenue and adjusted EBITDA margin, full-year adjusted EPS guidance, free cash flow, debt reduction, segment trends (Connected Tech, Essential Dental, Ortho/Implant, Wellspect), and any covenant or refinancing news.
Reduce confidence if the company misses guidance, signals a need for equity financing, loses share in clear aligners or digital dentistry, or lets adjusted margins compress.
Investment research summary
DENTSPLY SIRONA sells dental equipment (imaging, CAD/CAM, treatment centers), consumables (endodontics, restorative, anesthetics), orthodontic solutions (SureSmile), implants, and specialty urology catheters to dentists, labs, and hospitals. Customers pay for brand trust, installed base compatibility, distribution breadth, and clinical support.
The moat rests on installed equipment base, 140+ years of brand heritage, regulatory approvals, a global distributor network, and R&D in digital dentistry. It has narrowed under pressure from Align Technology in clear aligners and nimbler digital workflow competitors.
The thesis fails if the company cannot return to GAAP profitability, debt becomes unsustainable and forces equity dilution or asset sales, competitive losses in clear aligners and digital dentistry accelerate, or dental procedure volumes weaken with consumer spending.
CEO Daniel Scavilla, in place since August 1, 2025, is executing a restructuring around organizational simplification, digital transformation, and expanded distribution. CFO John Fortson joined on July 20, 2026. The team is credible, but capital allocation is constrained by about $2.35 billion of debt.
Dentistry benefits from aging demographics and growing cosmetic awareness. Digital transformation in intraoral scanning, CAD/CAM, 3D printing, and AI diagnostics is the key secular shift. Demand is steadier than elective surgery but still sensitive to consumer spending and financing conditions.
XRAY looks cheap on forward P/E near 9.6x and price/sales near 0.77x, but the market has already rewarded the turnaround with a roughly 50% rally, pushing the price above the consensus target. Margin of safety now depends on Q2 2026 results, debt reduction, and renewed GAAP profitability rather than on a depressed price.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| XRAY price | $14.13 reference close on August 3, 2026 | Google Finance and StockAnalysis.com market data | Aug 4, 2026 |
| Market capitalization | $2.83 billion, verified as $14.13 x 200.33 million shares with 0.02% variance | financial_rigor.py market cap verification | Aug 4, 2026 |
| Shares outstanding | 200.33 million shares, float 199.22 million | StockAnalysis.com and Yahoo Finance | Aug 4, 2026 |
| TTM revenue | Approximately $3.68 billion | StockAnalysis.com and Yahoo Finance | Aug 4, 2026 |
| TTM GAAP net income | -$628 million, or -$3.15 diluted EPS, including impairment and restructuring charges | StockAnalysis.com income statement | Aug 4, 2026 |
| FY2025 results | $3.68 billion revenue, down 2.98% year over year, and a -$598 million net loss | StockAnalysis.com financials | Aug 4, 2026 |
| Q1 2026 results | $880 million revenue, $0.27 adjusted EPS, 14.7% adjusted EBITDA margin | Dentsply Sirona press release and Google Finance | Aug 4, 2026 |
| Forward EPS estimate | About $1.42 to $1.47 adjusted EPS for FY2026 | StockAnalysis.com forecast (S&P Global) | Aug 4, 2026 |
| Cash and debt | $190 million cash; about $2.35 billion total debt; debt-to-equity ratio near 178% | StockAnalysis.com statistics | Aug 4, 2026 |
| Valuation snapshot | 9.6x forward P/E, 0.77x price/sales, 2.15x price/book, 27.2x price/FCF, 3.7% FCF yield, 4.5% dividend yield | financial_rigor.py valuation verification and StockAnalysis.com | Aug 4, 2026 |
| Analyst consensus | Hold, with an average 12-month target of $13.38 to $13.83 and a range of $9.00 to $17.00 | StockAnalysis.com forecast and Google Finance | Aug 4, 2026 |
| Technical snapshot | Above the 50-day ($11.49) and 200-day ($11.81) moving averages, near the $14.86 52-week high, RSI near 64 | StockAnalysis.com statistics and price history | Aug 4, 2026 |
This XRAY AI stock analysis is an informational research tool only. It is not investment advice, a recommendation, or a guarantee of future returns. Forecast scenarios are based on available public data as of August 4, 2026 and may be wrong if DENTSPLY SIRONA fundamentals, Q2 2026 results, restructuring execution, dental demand, debt costs, competitive dynamics, interest rates, regulation, or market valuation change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
